Based on yesterday's news release, BETonMACE has enrolled "over 1,750 patients enrolled, representing approximately 75 percent of total planned enrollment." The June 28th, 2017 news release stated "BETonMACE Phase 3 trial now has approximately 1,600 patients enrolled, representing approximately 67 percent of total planned enrollment." Planned enrollment is 2400 patients. Depending upon whether you go off of the percentages (67% vs. 75%) or the approximate numbers (1600 vs. 1750), it appears that only 150 to 200 patients were added in the two month period between June 28 and August 30. This averages out to ~100 patients per month for those two months.

After the start of randomization in Taiwan, the July 10, 2017 news release stated "With the addition of new active clinics in the [Taiwan] Territories, and soon in the Netherlands and in Russia, we remain on track for full enrollment in the study by the fall of 2017." Hopefully the addition of the Taiwan, Netherlands and Russia sites truly do get the enrollment back on track. They need to add ~600 patients between now and "the fall," whenever they define that to be.

BearDownAZ